Fierce Medtech Names Genesis Therapeutics a "Fierce 15" Company of 2023

Fierce Medtech's Fierce 15 of 2023

Andreessen Co-Leads $200 Million Investment in Biotech Startup Genesis Therapeutics

Andreessen Horowitz-backed start­up lands $200M for AI-based drug discovery

AI drug designer Genesis Therapeutics forges $200M round with eye on clinical testing

Genesis Therapeutics Closes Oversubscribed $200M Series B

Genesis Therapeutics announces AI discovery deal with Eli Lilly, $20M in upfront cash with potential total value of $670M

Genesis Therapeutics Announces Strategic Collaboration with Lilly to Discover Novel Therapies Using the Genesis Molecular AI Platform

Genesis Therapeutics Hires Will McCarthy as Chief Business Officer

Genesis Therapeutics Secures $52M Series A, Led by Rock Springs Capital

Genesis Therapeutics raises $52M A round for its AI-focused drug discovery mission

Genesis Therapeutics Enters AI-driven, Multi-Target Drug Discovery Partnership with Genentech

Roche's James Sabry partners Genentech with Stanford spin­out Genesis Therapeutics

Genentech taps Stanford University spinout for AI drug discovery partnership

AI 50: America’s Most Promising Artificial Intelligence Companies

30 Under 30: Healthcare 2020

Five Questions with a16z’s Vijay Pande on AI and Making New Drugs

Genesis Therapeutics Raises $4.1M Seed, Led by Andreessen Horowitz

An Interview with Evan Feinberg